Clinical Program BL8040

BioLineRx Doses First Patient for BKT-140/BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment

BioLineRx Doses First Patient for BKT-140/BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment

The results from the phase 1 trial expected by end of 2014 or early 2015. BKT-140/BL-8040 is also in the midst of a Phase 2 trial for AML, with results expected in early 2015.

September 3rd, 2014|Clinical Program BL8040, Recent News|

BioLineRx Receives Approval to Commence Phase 1 Trial for Novel Stem Cell Mobilization Treatmen

BioLineRx Receives Approval to Commence Phase 1 Trial for Novel Stem Cell Mobilization Treatment

The phase 1 trial of BKT-140/BL-8040 is expected to begin in Q3 2014, with results expected in late 2014 or early 2015. BKT-140/BL-8040 is also in Phase 2 for AML, with results expected in early 2015.

June 16th, 2014|Clinical Program BL8040|

Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment

BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment

A phase 1/2 study will assess the effect of BKT-140/BL-8040 in combination with standard therapy.

April 10th, 2014|Clinical Program BL8040|

BioLineRx Announces Issuance of United States Patent

BioLineRx Announces Issuance of United States Patent Covering Use of BKT-140/BL-8040 in Immunotherapy

BKT-140/BL-8040 is currently undergoing a Phase 2 trial for acute myeloid leukemia (AML) and is expected to commence a Phase 1 trial in stem cell mobilization in Q2 2014.

March 13th, 2014|Clinical Program BL8040|

Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia

BioLineRx Announces Positive Preclinical Results for Novel Treatment for Chronic Myeloid Leukemia

BKT-140/BL-8040 study published in Molecular Cancer Therapeutics.

BKT-140/BL-8040 is currently undergoing a Phase 2 trial for acute myeloid leukemia (AML) and is expected to commence a Phase 1 trial in stem cell mobilization in Q2 2014; top-line results from both trials are expected in Q4 […]

February 12th, 2014|Clinical Program BL8040|

BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment

BioLineRx Receives Orphan Drug Designation for Novel Stem Cell Mobilization Treatment

BKT-140/BL-8040 previously received Orphan Drug Designation for treatment of Acute Myeloid Leukemia.

BKT-140/BL-8040 is expected to commence Phase 1 trial in stem cell mobilization in Q2 2014, and top-line results are expected in H2 2014.

January 23rd, 2014|Clinical Program BL8040|

BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment

BioLineRx Announces Regulatory Submission for Novel Stem Cell Mobilization Treatment

The phase 1 Trial of BKT-140/BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014

BKT-140/BL-8040 is also in Phase 2 for AML; top-line results expected in H2 2014

January 13th, 2014|Clinical Program BL8040|

Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment

BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
Initial results for BKT-140/BL-8040 show substantial mobilization of cancer cells and signs of robust cancer cell death (apoptosis).

December 16th, 2013|Clinical Program BL8040|

Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference

BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference

BKT-140/BL-8040 is currently in Phase 2 study in AML patients, with partial results expected this month and final results expected in H2 2014.

December 10th, 2013|Clinical Program BL8040|

Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma

BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma

Results published in Clinical Cancer Research.

Additional clinical trial in stem cell mobilization expected to commence in H1 2014.

November 19th, 2013|Clinical Program BL8040|